123 related articles for article (PubMed ID: 38635940)
1. Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast Cancer-Associated Germline Pathogenic Variants in Mexico.
Mesa-Chavez F; Chavarri-Guerra Y; Aguilar-Y-Mendez D; Becerril-Gaitan A; Vaca-Cartagena BF; Carrillo-Bedoya A; Santiesteban-González S; Aranda-Gutierrez A; Rodríguez-Faure A; Obregon-Leal D; Quintero-Beuló G; Rodriguez-Olivares JL; Miaja M; Weitzel JN; Villarreal-Garza C
JCO Glob Oncol; 2024 Apr; 10():e2300417. PubMed ID: 38635940
[TBL] [Abstract][Full Text] [Related]
2. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
[TBL] [Abstract][Full Text] [Related]
3. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
[TBL] [Abstract][Full Text] [Related]
4. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
5. Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.
Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Deapen D; Morrow M; Jagsi R; Katz SJ
JAMA Oncol; 2020 Apr; 6(4):e196400. PubMed ID: 32027353
[TBL] [Abstract][Full Text] [Related]
6. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L
JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
8. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
10. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract][Full Text] [Related]
11. Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with
Roebothan A; Smith KN; Seal M; Etchegary H; Dawson L
Curr Oncol; 2023 Oct; 30(10):9367-9381. PubMed ID: 37887578
[TBL] [Abstract][Full Text] [Related]
12. Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment.
Mai PL; Lagos VI; Palomares MR; Weitzel JN
Ann Surg Oncol; 2008 Dec; 15(12):3415-21. PubMed ID: 18836779
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
[TBL] [Abstract][Full Text] [Related]
14. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
[TBL] [Abstract][Full Text] [Related]
15. Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers.
Lee EG; Kang HJ; Lim MC; Park B; Park SJ; Jung SY; Lee S; Kang HS; Park SY; Park B; Joo J; Han JH; Kong SY; Lee ES
Cancer Res Treat; 2019 Jan; 51(1):280-288. PubMed ID: 29747489
[TBL] [Abstract][Full Text] [Related]
16. Influence of germline test results on surgical decision making in women with invasive breast cancer.
Vargason AB; Turner CE; Shriver CD; Ellsworth RE
Cancer Genet; 2022 Aug; 266-267():81-85. PubMed ID: 35868102
[TBL] [Abstract][Full Text] [Related]
17. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
[TBL] [Abstract][Full Text] [Related]
18. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
19. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
[TBL] [Abstract][Full Text] [Related]
20. Communication about positive BRCA1 and BRCA2 genetic test results and uptake of testing in relatives in a diverse Asian setting.
Lee DS; Meiser B; Mariapun S; Hassan T; Yip CH; Mohd Taib NA; Teo SH; Thong MK; Yoon SY
J Genet Couns; 2021 Jun; 30(3):720-729. PubMed ID: 33245177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
